The Cancer Letter
@cancerletter.com
The leading independent source for information on the issues that shape oncology since 1973. cancerletter.com
DNA atlas could power the next generation of AI drug discovery,@salkinstitute.bsky.social and @arcinstitute.org led study finds https://cancerletter.com/clinical-roundup/20260731_7c/
DNA atlas could power the next generation of AI drug discovery, Salk-led study finds - The Cancer Letter
Researchers at the Salk Institute and Arc Institute and their collaborators unveiled the first body-wide single-cell atl
cancerletter.com
Kate Markey named Innovators Network Endowed Chair at @fredhutch.org https://cancerletter.com/in-brief/20260731_6c/
Kate Markey named Innovators Network Endowed Chair at Fred Hutch - The Cancer Letter
Kate Markey, an assistant professor at Fred Hutch Cancer Center and UW Medicine, has recently been named the next holder
cancerletter.com
Buchwald/Lowe (@winshipcancer.emory.edu): "In the context of immunology, decades of work have established that the immune system is profoundly regulated by the circadian clock." https://cancerletter.com/trials-and-tribulations/20260731_3/
Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation - The Cancer Letter
The recent retraction of the LungTIME-C01 randomized trial evaluating chrono-modulated immunotherapy in non-small cell l
cancerletter.com
BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds https://cancerletter.com/clinical-roundup/20260731_7b/
BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds - The Cancer Letter
A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Br
cancerletter.com
Pamela Munster named inaugural associate director for early detection and interception research at @stanford-cancer.bsky.social https://cancerletter.com/in-brief/20260731_6b/
Pamela Munster named inaugural associate director for early detection and interception research at Stanford - The Cancer Letter
Pamela Munster will join the Stanford Cancer Institute as the inaugural associate director for early detection and inter
cancerletter.com
“There is a reason why generics have been exempt from all the tariffs until now,” said Marta Wosińska, @brookings.edu healthcare economist and senior fellow. “And the reason is not as much the cost, but how tariffs might impact availability of drugs.” https://cancerletter.com/white-house/20260731_2/
Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages “There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - The Cancer Letter
In his latest set of sweeping tariffs on the pharmaceutical industry, President Donald Trump has announced a 200% levy o
cancerletter.com
Of the hundreds of scientists Joseph F. Fraumeni Jr. mentored, perhaps one of the closest was Stephen J. Chanock, who worked with Fraumeni for 25 years. Chanock spoke with Otis Brawley about their illustrious mentor. https://cancerletter.com/cancer-history-project/20260731_4/
Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people” Chanock and Brawley reflect on their illustrious mentor - The Cancer Letter
If a Mount Rushmore of Epidemiology were to exist, Joseph F. Fraumeni Jr. would be etched into the face of the mountain,
cancerletter.com
@who.int projects new cancer cases will rise to 35 million by 2050 globally https://cancerletter.com/cancer-policy/20260731_5c/
WHO projects new cancer cases will rise to 35 million by 2050 globally - The Cancer Letter
In a new report, the World Health Organization called for urgent action to address cancer, projecting that new cases wil
cancerletter.com
Cancer researchers say that they are concerned about gambling creating opportunities for insider trading, undermining the integrity of clinical trials, eroding equipoise, and diminishing public trust in biomedical research. https://cancerletter.com/news-analysis/20260731_1/
Prediction markets now allow betting on clinical trial results, FDA decisions It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - The Cancer Letter
Prediction market exchanges have allowed the public to bet on the ousting of Nicolás Maduro, the outcome of the Spain v.
cancerletter.com
Monica L. Baskin named director of @vcumassey.bsky.social Baskin is the first female director of Massey and the first Black woman to be named director of a NCI-designated Cancer Center. https://cancerletter.com/in-brief/20260731_6a/
Buchwald/Lowe (@winshipcancer.emory.edu): "The recent retraction of the LungTIME-C01 randomized trial...has ignited a vigorous debate regarding the promise of cancer chronotherapy." https://cancerletter.com/trials-and-tribulations/20260731_3/
Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds https://cancerletter.com/clinical-roundup/20260731_7a/
cancerletter.com
EMA CHMP recommends approval for biosimilar Denosumab Ascend and Nylaspeg, recommends against Tacquell https://cancerletter.com/drugs-and-targets/20260731_8b/
cancerletter.com
HHS releases government-wide policy to prohibit gain-of-function research https://cancerletter.com/cancer-policy/20260731_5b/
cancerletter.com
After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug https://cancerletter.com/drugs-and-targets/20260731_8a/
cancerletter.com
In his latest set of sweeping tariffs on the pharmaceutical industry, Trump has announced a 200% levy on imported generic drugs by the year 2029. The worry ringing loud in the minds of many oncologists is a familiar one: Shortages. https://cancerletter.com/white-house/20260731_2/
cancerletter.com
Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation By Zachary S. Buchwald and Michael C. Lowe (@winshipcancer.emory.edu) https://cancerletter.com/trials-and-tribulations/20260731_3/
cancerletter.com
FDA’s OCE publishes three final guidances to increase clinical trial enrollment https://cancerletter.com/cancer-policy/20260731_5a/
Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people” Chanock and Brawley reflect on their illustrious mentor https://cancerletter.com/cancer-history-project/20260731_4/
cancerletter.com
How’s this for a bet: Will FDA approve daraxonrasib this year? Now, gamblers can place bets on the outcomes of clinical trials and FDA decisions. The Cancer Letter asked five experts and organizations to weigh the consequences. https://cancerletter.com/news-analysis/20260731_1/
cancerletter.com
Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages “There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns https://cancerletter.com/white-house/20260731_2/
Prediction markets now allow betting on clinical trial results, FDA decisions It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake https://cancerletter.com/news-analysis/20260731_1/
Prediction markets now allow betting on clinical trial results, FDA decisions It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - The Cancer Letter
Prediction market exchanges have allowed the public to bet on the ousting of Nicolás Maduro, the outcome of the Spain v.
cancerletter.com
Should one screen an asymptomatic population for a condition that no major medical society recommends screening for? That’s where many experts draw the line. https://cancerletter.com/podcastc/20260729-trt/
Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there? - The Cancer Letter
Last week, the Pentagon posted a video on X announcing they will be mandating testosterone screening for troops in the m
cancerletter.com
Chemo resistance in ovarian cancer may be reversible with existing drugs, @wistar.org study finds https://cancerletter.com/clinical-roundup/20260724_7d/
Chemo resistance in ovarian cancer may be reversible with existing drugs, Wistar study finds - The Cancer Letter
Scientists at The Wistar Institute have identified a mechanism behind the chemotherapy resistance that makes ovarian cancer so lethal. The researchers showed that chemotherapy triggers an inflammatory cascade that recruits immune cells into the tumor microenvironment, which ultimately function to protect the cancer from subsequent chemotherapy. To access this subscriber-only content please log in or […]
cancerletter.com
“As always, unjustified use of a screening test and subsequent therapeutic intervention can have unintended consequences without clear benefit," Barnett Kramer, former director of the NCI Division of Cancer Prevention said to The Cancer Letter. https://cancerletter.com/regulatory-news/20260724_2/
Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings Experts caution the move amounts to a “huge, unregulated, natural experiment” - The Cancer Letter
In a video captioned “The High-T Department of War” and posted on X, Secretary of Defense Pete Hegseth announced that he was authorizing a screening program for troops to ensure “you have the right testosterone levels to operate at your absolute best.” To access this subscriber-only content please log in or subscribe.If your institution has […]
cancerletter.com
@unm.edu Comprehensive Cancer Center installs MRI-linear accelerator https://cancerletter.com/in-brief/20260724_6d/
UNM installs MRI-linear accelerator - The Cancer Letter
The University of New Mexico Comprehensive Cancer Center has installed an MRI-linear accelerator. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe
cancerletter.com
Morrow (@wilmotcancer.bsky.social) had a deep commitment to “helping good people through lousy times,” as he liked to say. His groundbreaking research contributed to the need for anti-emetic drugs to control nausea and vomiting during chemotherapy. https://cancerletter.com/obituary/20260724_4/
https://cancerletter.com/obituary/20260724_4/
No description found
cancerletter.com
The Pentagon announced they will be mandating testosterone screening for soldiers aged 30 and up. If they test low, they will be offered voluntary treatment. Experts warn, "this is basically an uncharted, natural, human experiment." https://cancerletter.com/podcastc/20260729-trt/
Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there? - The Cancer Letter
Last week, the Pentagon posted a video on X announcing they will be mandating testosterone screening for troops in the m
cancerletter.com
Retesting with at-home FIT tests is linked to earlier diagnoses, retrospective cohort study finds https://cancerletter.com/clinical-roundup/20260724_7c/
Retesting with at-home FIT tests is linked to earlier diagnoses, retrospective cohort study finds - The Cancer Letter
Repeat testing is tied to earlier diagnoses and shaped by health-system outreach, according to a retrospective cohort study of nearly 500,000 adults. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored […]
cancerletter.com
@nbccstopbc.bsky.social open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act https://cancerletter.com/cancer-policy/20260724_5d/
NBCC’s open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act - The Cancer Letter
NBCC President Fran Visco authored the following open letter to the House Ways and Means Committee, criticizing the committee for failing to bring the Metastatic Breast Cancer Access to Care Act, HR 2048, before the committee for markup. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log […]
cancerletter.com